PharmaSeek, LLC

1. Romark Laboratories, LC $3,520,342 20 payments
2. VIVUS, Inc. $485,404 33 payments
3. Genentech, Inc. $352,420 54 payments
4. Ironwood Pharmaceuticals, Inc $283,599 47 payments
5. Teva Pharmaceuticals USA, Inc. $192,156 24 payments
6. Dr.Reddy's Laboratories,Inc. $26,100 5 payments
7. Sumitomo Pharma America, Inc. $23,595 12 payments
8. Avanir Pharmaceuticals, Inc. $15,788 9 payments
9. Kowa Research Institute, Inc. $12,406 7 payments
10. OraSure Technologies Inc. $3,000 3 payments

1. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $3,182,955 14 payments
2. A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject $411,048 23 payments
3. A Phase Ib Randomized Blinded Placebo Controlled Multiple Ascending Dose Study With Bfkb8488a $352,420 54 payments
4. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $337,387 6 payments
5. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $189,127 22 payments
6. C3718-301 $135,768 12 payments
7. McP-103-312 $87,613 18 payments
8. A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject $74,356 10 payments
9. McP-103-205 $37,568 11 payments
10. A Phase 3 randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan or MabThera $26,100 5 payments

1. Other $485,404 33 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.